DelveInsight's 'BREYANZI Market Size, Forecast, and Market Insight Report' highlights the details around BREYANZI, a CD19-directed CAR ...

BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies ...

T-cell lymphoma is a rare cancer that affects the lymphatic system. Learn about the types, signs, symptoms, treatments, and ...

Investigators found that lipid metabolism disruptions spark T-cell dysfunction in patients with chronic lymphocytic leukemia.

During a Case-Based Roundtable® event, Natalie Galanina, MD, reviewed how outcomes have changed in patients with primary ...

Fred Locke, MD, Moffitt Cancer Center, explains why this hematologic cancer is such an attractive target for chimeric antigen ...

Black women with chronic myeloid leukemia face unique challenges when it comes to diagnosis, treatment, and overall disease ...

Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed a non-chemotherapy treatment regimen ...

A longitudinal multiomics analysis of a patient with multiple myeloma who developed peripheral T cell lymphoma after treatment with anti-BCMA CAR T cells and a GPRC5D-directed bispecific antibody ...

"Three weeks later, I had 10 more tumors come down my spine. So they told me at first I had mediastinum lymphoma, 3B, which is really aggressive lymphoma. At that point, I'm like, ‘okay ...